Genomics

C2i Genomics Raises $100M for Whole-Genome Cancer Treatment Intelligence Platform

  • by

– Cancer intelligence company, C2i Genomics announced it has raised $100M in financing from Casdin Capital, NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others. – Funds will be used to accelerate clinical development and commercialization of the company’s C2-Intelligence Platform, a… Read More »C2i Genomics Raises $100M for Whole-Genome Cancer Treatment Intelligence Platform

AWS Launches Next Phase of Diagnostic Development Initiative

  • by

What You Should Know: – Today, Amazon Web Services (AWS) launched the next phase of Diagnostic Development Initiative and expanded funding scope. – In the first phase of the initiative, AWS has supported 87 organizations to date through this effort ranging from startups, nonprofits, research institutions, and businesses in 17 countries and awarded $8 million in computing credits… Read More »AWS Launches Next Phase of Diagnostic Development Initiative

Frenova Begins Patient Enrollment to Build World’s Largest Genomics Registry for Kidney Disease

  • by

What You Should Know: – Frenova Renal Research, a global division of Fresenius Medical Care, announced today that it has started to enroll patients in its new endeavor to build the world’s largest genomics registry targeting kidney disease. – The registry will be used to help… Read More »Frenova Begins Patient Enrollment to Build World’s Largest Genomics Registry for Kidney Disease

Nebula Gives Users Ownership Of Their Personal Genomic Data with Oasis Integration

  • by

What You Should Know: – Nebula Genomics announces integration with Oasis Labs to give its customers full ownership and control of the data received from their comprehensive genome sequencing tests. – Through Oasis Labs’ unique privacy solution Parcel, Nebula’s users will be able to retain… Read More »Nebula Gives Users Ownership Of Their Personal Genomic Data with Oasis Integration

Bionano Genomics Acquires Lineagen to Facilitate the Clinical Adoption of Saphyr for Digital Cytogenetics

  • by

Shots: Lineagen to receive $9.6M consisting of 6,167,510 shares of Bionano’s common stock, ~ $1.7M in cash and assumption of ~$2.9M in liabilities. The acquisition complements Binano by adding leading cytogeneticists, genetic counselors, laboratory operations and billing experts, clinical commercialization experts, and payor contracts The… Read More »Bionano Genomics Acquires Lineagen to Facilitate the Clinical Adoption of Saphyr for Digital Cytogenetics

Founders’ story: Seven Bridges

  • by

A Q&A with executives from Seven Bridges, a bioinformatics analysis business, highlights the company’s work in the precision medicine sector.